Amryt Reports Record Q1 2021 Financial and Operating Results
Amryt Reports Record Q1 2021 Financial and Operating Results 8.7% YoY revenue growth in the quarter to $48.4M 16.5% YoY underlying revenue growth excluding the impact of a LATAM periodic order in Q1 2020 5th consecutive quarter of positive EBITDA generation National reimbursement achieved for metreleptin in England, Wales and France Regulatory submissions for Oleogel-S101 (Filsuvez®) made to the FDA and EMA Raising FY 2021 revenue guidance to $205M - $210M Today announced proposed acquisition of Chiasma, Inc. (NASDAQ:CHMA) Conference call and webcast today at 0830 EDT / 1330 BST DUBLIN, Ireland, and Boston MA, May 5, 2021, Amryt (NASDAQ:AMYT, AIM: AMYT))), a global, commercial-stag
